Study Reports Combination Therapy Using Two Nanoparticles to Treat Massive Hemorrhage

Mbadive haemorrhage, or excessive bleeding, is a potentially preventable and major cause of death in traumatized patients.

An immediate and well-balanced transfusion of blood components, such as platelets and red blood cells, which respectively form clots to stop bleeding and deliver oxygen to tissues and organs for proper function, becomes crucial. for their survival.

Unfortunately, blood products may not always be in stock in an emergency, for example in case of a serious accident involving a large number of drivers and pbadengers, as they can not be kept long. For example, a packet of red blood cells can only be stored for 3 weeks at 2 to 6 ° C. It only takes four days at room temperature for a platelet concentrate and must be stirred constantly in a shaker.

To replace these components, a Japanese research team successfully resuscitated rabbits with coagulopathy or impaired ability to form blood clots, following severe hemorrhagic shock, using two different nanoparticles; one with hemostatic potential and the other with potential oxygen carrier.

Shinji Takeoka of Waseda University said, "Our results suggest that the nanoparticles we have developed possess excellent preservation property, but also that combination therapy using hemostatic nanoparticles and nanoparticles carrying oxygen is comparable to conventional transfusion. "

This study, published in Transfusion, is the first to report a combination therapy using two different types of functional nanoparticles.

"In this experiment, the research team entered the rabbit's liver with abnormally low platelet levels to induce mbadive hemorrhage and administered the developed hemostatic nanoparticles in a previous study while blocking the bleeding site immediately." after an injury, "said Manabu Kinoshita, National Defense. Japan College explains. "After five minutes, coagulation was confirmed and nanoparticles carrying oxygen were administered to help the rabbits recover from anemia due to blood loss.

As a result, six out of ten rabbits treated with this new combined therapy survived compared to seven in ten by conventional transfusion of platelet concentrates and RBCs, showing similar control of bleeding.

Hiromi Sakai, from Nara Medical University, said: "The hemostatic particles that we have developed can be stored for about a year at room temperature, without any agitation.Also for nanoparticles carrying the In addition, oxygen-carrying nanoparticles do not need any type of blood test or compatibility test.

The team believes that combined therapy using these nanoparticles will be effective for both hospital care and prehospital resuscitation.

In addition, given that the blood supply is expected to decline in countries with low birth rates and aging population, such as Japan, the team hopes that the nanoparticles will be used in the future. future for practical applications to save the lives of patients requiring mbadive transfusion in case of emergency trauma. care.